Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology firm, announced that CEO Ivana Magovčević-Liebisch will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET. The event will be accessible via live webcast on their website, with an archived replay available for 90 days post-presentation. Vigil focuses on therapies for neurodegenerative diseases, notably through their lead candidate VGL101, which is in a Phase 2 trial for a rare disease known as ALSP.

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41^st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET.

To access a live webcast of these presentations, please visit “Events & Presentations” in the “Investors” section of the Vigil website at www.vigilneuro.com.  An archived replay for each will be available for approximately 90 days following the presentation.

About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the 'Investors' section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

FAQ

When is Vigil Neuroscience's presentation at the J.P. Morgan Healthcare Conference?

Vigil Neuroscience's presentation is scheduled for January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET.

Who will present for Vigil Neuroscience at the conference?

Ivana Magovčević-Liebisch, Ph.D., J.D., the President and CEO, will present for Vigil Neuroscience.

How can I watch Vigil Neuroscience's conference presentation?

The presentation will be available via live webcast on Vigil's website in the 'Events & Presentations' section.

What is the focus of Vigil Neuroscience's therapeutic development?

Vigil Neuroscience focuses on developing treatments for neurodegenerative diseases by restoring microglial function.

What is VGL101 and what is its current trial status?

VGL101 is Vigil's lead candidate, currently in a Phase 2 proof-of-concept trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).